Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nektar Therapeutics
JAMA reports on the COVID-19 Prevention Network’s efforts. Also, Inhibikase said the US FDA lifted a hold on its drug for Parkinson’s disease, while Astellas Pharma said the agency lifted a clinical hold on its gene therapy for Pompe disease. And Trefoil, Theriva Biologics and Nektar initiated new trials.
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Siemens Healthineers reported strong increases revenues and order bookings for its fiscal 2022, but it is realigning its radiation oncology businesses and changing its IVD business structure.
- Drug Delivery
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Aerogen, Inc.
- Inhale Therapeutic Systems, Inc.
- Inheris Biopharma, Inc.
- Nektar Therapeutics (India) Private Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.